A5055128103- Tryptophan and brain disorders
- Stress Responses and Cortisol
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Receptor Mechanisms and Signaling
- Bipolar Disorder and Treatment
- Neuroendocrine regulation and behavior
- Schizophrenia research and treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Neuropeptides and Animal Physiology
- Nicotinic Acetylcholine Receptors Study
- Neural dynamics and brain function
- Functional Brain Connectivity Studies
- Advanced Neuroimaging Techniques and Applications
- Treatment of Major Depression
- Multiple Sclerosis Research Studies
- Adipose Tissue and Metabolism
- Neuroscience of respiration and sleep
- Mental Health Research Topics
- Neuroscience and Neural Engineering
- Advanced MRI Techniques and Applications
- Lipid Membrane Structure and Behavior
- Phosphodiesterase function and regulation
- Child Nutrition and Feeding Issues
- Epigenetics and DNA Methylation
Karolinska Institutet
2016-2025
Lithuanian Sports University
2024-2025
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
2024
University of Tübingen
2024
University of Oslo
2011-2020
Oslo University Hospital
2011-2020
Linköping University
2010-2015
Karolinska University Hospital
2011-2015
Science for Life Laboratory
2015
AstraZeneca (Sweden)
2015
The kynurenic acid (KYNA) hypothesis for schizophrenia is partly based on studies showing increased brain levels of KYNA in patients. an endogenous metabolite tryptophan (TRP) produced astrocytes and antagonizes N-methyl-D-aspartate α7* nicotinic receptors. formation determined by the availability substrate, hence, we analyzed its precursors, kynurenine (KYN) TRP, cerebrospinal fluid (CSF) patients with schizophrenia. CSF from male olanzapine treatment (n = 16) was compared healthy...
Accumulating evidence indicates that schizophrenia is associated with brain immune activation. While a number of reports suggest increased cytokine levels in patients schizophrenia, many these studies have been limited by their focus on peripheral cytokines or confounded various antipsychotic treatments. Here, well-characterized all receiving olanzapine treatment, and healthy volunteers were analyzed regard to cerebrospinal fluid (CSF) cytokines. We correlated the CSF previously metabolites...
<h3>Background:</h3> In recent years, a role for the immune system in pathogenesis of psychiatric diseases has gained increased attention. Although bipolar disorder appears to be associated with altered serum cytokine levels, putative immunological contribution its patho-physiology remains established. Hitherto, no direct analyses cerebrospinal fluid (CSF) cytokines patients have been performed. <h3>Methods:</h3> We analyzed CSF concentrations euthymic diagnosed type I (<i>n</i> = 15) or II...
Several studies suggest a role for kynurenic acid (KYNA) in the pathophysiology of schizophrenia. It has been proposed that increased brain KYNA levels schizophrenia result from pathological shift kynurenine pathway toward enhanced formation, away other branch leading to quinolinic (QUIN). Here we investigate QUIN cerebrospinal fluid (CSF) patients with and healthy controls, relate those CSF metabolites same individuals. stable outpatients treated olanzapine (n = 22) controls 26) were...
Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic (KYNA) have consistently been implicated in schizophrenia and bipolar disorder. Here, we conducted a genome-wide association study based on CSF KYNA disorder found support for an with common variant within 1p21.3. After replication independent cohort, linked this genetic variant-associated reduced SNX7 expression-to positive psychotic symptoms executive function deficits A...
Schizophrenia is a neurodevelopmental disorder characterized by an excessive loss of synapses. Kynurenic acid (KYNA), neuroactive metabolite tryptophan along the kynurenine pathway, can induce schizophrenia-related phenotypes in rodents, and clinical studies have revealed elevated KYNA levels CNS individuals with schizophrenia. However, factors that cause schizophrenia, mechanisms which contributes to pathophysiology, remain largely elusive. The authors used patient-derived cellular modeling...
<h3>Background:</h3> Patients with schizophrenia show elevated brain levels of the neuroactive tryptophan metabolite kynurenic acid (KYNA). This astrocyte-derived mediator acts as a neuroprotectant and modulates sensory gating cognitive function. We measured KYNA in cerebrospinal fluid (CSF) patients bipolar disorder healthy volunteers to investigate putative involvement disorder. <h3>Methods:</h3> obtained CSF by lumbar puncture from 23 men 31 euthymic analyzed samples using...
Olsson SK, Sellgren C, Engberg G, Landén M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients bipolar I disorder. Bipolar Disord 2012: 14: 719–726. © 2012 The Authors. Journal compilation John Wiley & Sons A/S. Objectives: Kynurenic (KYNA), an end metabolite of tryptophan degradation, antagonizes glutamatergic cholinergic receptors the brain. Recently, we reported elevated levels cerebrospinal (CSF) KYNA male Here, investigate...
Abstract Metabolites of the kynurenine pathway tryptophan degradation, in particular, N -Methyl- d -aspartic acid receptor antagonist kynurenic (KYNA), are increasingly recognized as primary pathophysiological promoters several psychiatric diseases. Studies analyzing central KYNA levels from subjects with psychotic disorders have reported increased levels. However, sample sizes limited and contrast many larger studies examining this compound blood patients commonly report a decrease. A major...
Abstract Background Recent magnetic resonance spectroscopy (MRS) studies report that glutamine is altered in the brains of schizophrenic patients. There were also conflicting findings on glutamate cerebrospinal fluid (CSF) patients, and absent for glutamine. This study aims to clarify question CSF first episode drug naive Method Levels 25 drug-naive male patients 17 age-matched healthy controls measured by a high performance liquid chromatography. Results The ratio (126.1 (median), 117.7 ±...
Abstract Previous electrophysiological experiments have emphasized the importance of firing pattern for functioning midbrain dopamine (DA) neurons. In this regard, excitatory amino acid receptors appear to constitute an important modulatory control mechanism. present study, extracellular recording techniques were used investigate significance GABA B ‐receptor activation properties DA neurons in substantia nigra (SN) rat. Intravenous administration agonist baclofen (1–16 mg/kg) was associated...
Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite kynurenine pathway, its formation indirectly depends on activity 3-monooxygenase (KMO), enzyme converting to 3-hydroxykynurenine.We analyzed association between KMO gene polymorphisms CSF KYNA in patients healthy controls. Fifteen single nucleotide (SNPs) were selected covering...